The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …
Prevalence of targetable mutations in Black patients with lung cancer: a systematic review and meta-analysis
PURPOSE: Inferior outcomes of Black patients with lung cancer compared with other racial
groups are often linked to socioeconomic factors. It is crucial to determine whether a varying …
groups are often linked to socioeconomic factors. It is crucial to determine whether a varying …
[HTML][HTML] The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC)
HH Ramadhan, DF Taaban… - Asian Pacific Journal of …, 2021 - ncbi.nlm.nih.gov
Objective: Non-Small Cell Lung Cancer (NSCLC) Carcinogenesis could be caused by
numerous genetic mutations, one of the most common is the mutation in the Epidermal …
numerous genetic mutations, one of the most common is the mutation in the Epidermal …
[HTML][HTML] EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer
A Hung, KM Lee, PR Alba, Y Li, AZ Gao… - Cancer Treatment and …, 2021 - Elsevier
Background Epidermal growth factor receptor (EGFR) mutation testing is recommended in
metastatic non-small cell lung cancer (NSCLC). The objective of this study was to assess …
metastatic non-small cell lung cancer (NSCLC). The objective of this study was to assess …
[PDF][PDF] Prevalence and Patterns of EGFR Mutations in Non-Small Cell Lung Cancer in the Middle East and North Africa: A Systematic Review
Y Boustany, A Laraqui, H El Rhaffouli, T Bajjou… - 2021 - scholar.archive.org
Methods We conducted a systematic review of literature published on EGFR mutation
prevalence and its association with geographic region/country and clinicpathological …
prevalence and its association with geographic region/country and clinicpathological …
Investigating targeted driver mutations and PD-L1 expression for improved therapy of non-small cell lung cancer
A Alwithenani - 2021 - dalspace.library.dal.ca
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment
options to chemotherapy. New therapies that target driver gene mutations, are used to treat …
options to chemotherapy. New therapies that target driver gene mutations, are used to treat …